JointHealth™ express January 21, 2016
Quebec’s INESSS wants to hear your comments on apremilast (Otezla®) and adalimumab (Humira®)
Do you have psoriatic arthritis or juvenile arthritis or care for someone who does? We need your valuable input.
The National Institute of excellence in health and social services (INESSS) in Quebec is asking health professionals, consumers and patients, and patient groups to submit their comments about apremilast (Otezla®) for the treatment of psoriatic arthritis and adalimumab (Humira®) for the treatment of juvenile arthritis. These medications are being evaluated as part of the 2016 update to the List of Medications.
Consumers or patient groups can submit comments on the potential effects of a drug product on the condition of patients or consumers. You can give input if you are a Quebec resident. You must provide input by 11:59pm Eastern Standard Time on Thursday, January 28, 2016. Please send your comments by email to plan.commentaires.inscription@inesss.qc.ca.
Alternatively, you can email us your input at feedback@jointhealth.org or call us at 604-974-1366. We can send it as a patient group on your behalf. Please provide the input to us by Wednesday, January 27 so that we may submit your feedback in time.
Please note INESSS requires that all participants in the evaluation process disclose any conflict of interest to ensure the objectivity and credibility of the process. All comments submitted must be accompanied by a declaration of all conflicts of interest that may influence or appear to influence the information provided. This information is required in the interest of transparency, and the declaration of a conflict of interest does not necessarily mean the information will be rejected.
Quebec’s INESSS wants to hear your comments on apremilast (Otezla®) and adalimumab (Humira®)
Do you have psoriatic arthritis or juvenile arthritis or care for someone who does? We need your valuable input.
The National Institute of excellence in health and social services (INESSS) in Quebec is asking health professionals, consumers and patients, and patient groups to submit their comments about apremilast (Otezla®) for the treatment of psoriatic arthritis and adalimumab (Humira®) for the treatment of juvenile arthritis. These medications are being evaluated as part of the 2016 update to the List of Medications.
Consumers or patient groups can submit comments on the potential effects of a drug product on the condition of patients or consumers. You can give input if you are a Quebec resident. You must provide input by 11:59pm Eastern Standard Time on Thursday, January 28, 2016. Please send your comments by email to plan.commentaires.inscription@inesss.qc.ca.
Alternatively, you can email us your input at feedback@jointhealth.org or call us at 604-974-1366. We can send it as a patient group on your behalf. Please provide the input to us by Wednesday, January 27 so that we may submit your feedback in time.
Please note INESSS requires that all participants in the evaluation process disclose any conflict of interest to ensure the objectivity and credibility of the process. All comments submitted must be accompanied by a declaration of all conflicts of interest that may influence or appear to influence the information provided. This information is required in the interest of transparency, and the declaration of a conflict of interest does not necessarily mean the information will be rejected.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.